Scleroderma News and Research

Latest Scleroderma News and Research

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test. The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.

9 Nov 2010

New iPSC cell lines could help in treating patients with lung diseases

A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could possibly lead to new treatments for these debilitating diseases.

29 Oct 2010

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

29 Oct 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

Amira submits IND application for AM152 antagonist

Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

28 Sep 2010

New federal funds to create first national patient registry for pulmonary fibrosis

During the 8th annual National Pulmonary Fibrosis (PF) Awareness Week, Sept. 11 to 18, the Coalition for Pulmonary Fibrosis (CPF) met with over 45 legislators, both Representatives and Senators, and as of this date there are 139 House co-sponsors for the Pulmonary Fibrosis Research Enhancement Act (PFREA) to fund research on this deadly disease.

24 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Researchers to conduct gene analysis for ankylosing spondylitis

A new study designed to test suspected links between genes and two immune disorders could open the door to better ways to diagnose and treat the conditions that affect a combined total of approximately 2.5 million people in the United States, report scientists at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.

26 Aug 2010

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis (CPF) and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to continue to fund Pulmonary Fibrosis (PF) research.

24 Aug 2010

CPF urges people to consider clinical trials for pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is urging the more than 128,000 people known to suffer from the deadly lung disease, pulmonary fibrosis (PF), to consider clinical trials, including two new ones funded by the National Institutes of Health (NIH). Clinical trials of potential drug therapies are critical to the discovery of treatments for any disease and for a disease like PF that claims as many lives each year as breast cancer with virtually no survivors, they are the likely path to answers and saved lives.

13 Aug 2010

CPF announces nationwide advertising campaign to increase awareness about PF

The Coalition for Pulmonary Fibrosis announced today a nationwide advertising campaign to spread the word about Pulmonary Fibrosis is underway in an untraditional setting – on the nation's interstates. Together, a billboard ad and truck ads are part of a nationwide campaign to raise eyebrows and awareness of the deadly lung disease.

30 Jul 2010

Research findings link some autoimmune disorders with cancer

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

8 Jul 2010

NBC's TODAY Show to focus on PF in an interview with a patient from California

The Coalition for Pulmonary Fibrosis announced today one of the first major national media coverage opportunities for the CPF and Pulmonary Fibrosis. NBC's TODAY Show will focus on the disease in an interview with California patient Bob O'Rourke, who suffers from the disease and will die from it unless he receives a lung transplant in time.

15 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Actelion Pharmaceuticals US, Inc. is announcing the availability of the Pulmonary Arterial Hypertension Mobile Reference Guide, the first multimedia smart phone application that provides information on PAH disease, pathology, diagnosis, and treatment guidelines to healthcare professionals.

10 Jun 2010

Scleroderma News and Research

Latest Scleroderma News and Research

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Special Surgery investigators to present future of clinical care at ACR annual meeting

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New iPSC cell lines could help in treating patients with lung diseases

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Amira submits IND application for AM152 antagonist

New federal funds to create first national patient registry for pulmonary fibrosis

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Researchers to conduct gene analysis for ankylosing spondylitis

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

CPF urges people to consider clinical trials for pulmonary fibrosis

CPF announces nationwide advertising campaign to increase awareness about PF

Research findings link some autoimmune disorders with cancer

NBC's TODAY Show to focus on PF in an interview with a patient from California

New path involving "innocent spectators" to defeat systemic sclerosis

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Scleroderma News and Research

Latest Scleroderma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in